-
Global Biotechnology & Pharmaceutical Markets1 month agoSummit, BioNTech, more headline WCLC with next-gen lung cancer drugs
BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and...
-
Global Biotechnology & Pharmaceutical Markets1 month agoNovo Nordisk rebrands as Novo as new CEO charts turnaround
Embroiled in a fight to retain market share in weight loss and diabetes therapies, Novo Nordisk has rebranded and launched a new corporate culture.
-
Global Biotechnology & Pharmaceutical Markets2 months agoNo more Nordisk as Novo goes it alone amid rebranding push
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major...
-
Global Biotechnology & Pharmaceutical Markets2 months agoSTAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
-
Global Biotechnology & Pharmaceutical Markets2 months agoTakeda’s Plump, GV’s Yeshwant announce retirement plans
BIOCENTURY | MANAGEMENT TRACKSTAKEDA’S PLUMP, GV’S YESHWANT ANNOUNCE RETIREMENT PLANSAndy Plump has helped remake Japanese pharma an innovative global player
-
Global Biotechnology & Pharmaceutical Markets2 months agoSTAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of wastewater treatment.
-
Global Biotechnology & Pharmaceutical Markets2 months agoSamsung Biologics inks $262M manufacturing deal with European pharma company
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
-
Global Biotechnology & Pharmaceutical Markets2 months agoUK review recommends ‘L plates’ for new healthcare AIs
A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44 recommendations to set it right.
-
Global Biotechnology & Pharmaceutical Markets2 months ago
Fierce Pharma Asia—Takeda’s R&D leadership change; Daiichi’s $1.3B court win; New Samsung Bio contract
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit. Samsung Biologics signed a $262 million...
-
Global Biotechnology & Pharmaceutical Markets2 months ago
Singapore launches biotech-focused Boston hub to build on ‘centuries-old bond’
Officials rubbed shoulders with business leaders in a 19th-floor meeting room to celebrate the launch of Singapore’s newest Overseas Centre.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
